🏛️ Verified NIH Record • Updated 2025-10-10

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation (NCT04476953)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Mayo Clinic

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (13 items) and avoid the listed exclusions (29 items).

Location: Mayo Clinic in Rochester — Rochester, Minnesota

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria - Patients who meet any of the following exclusion criteria are not to be enrolled in this study. General Exclusion Criteria
  • Presence of any condition that the Investigator or the subject's attending physician believes would put the subject at risk or would preclude the patient from successfully completing the trial
  • Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative pregnancy test within 72 hours prior to randomization
  • WCBP who are unwilling to abstain from sex or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration
  • Men who are unwilling to abstain from sex with WCBP or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration Laboratory Exclusion Criteria
  • Total bilirubin \>3X upper limit of normal or as per clinical judgment.
  • Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) \>4x the upper limits of normal or as per clinical judgment.
  • Hemoglobin \<7 g/dL; white blood cell count ≤ 2,000/mm3 (\< or = 2.0 x 109/L) or \> or = 20,000/mm3 (\> or = 20 x 109/L); platelet count \< or = 40,000/µL (\< or = 40 x 109/L); absolute neutrophil count \< or = 1 x 109/L; lymphocyte count \<0.3 x 109/L at screening or as per clinical judgment.
  • Unstable (as per clinical judgment) major cardiovascular, renal, endocrine, immunological, or hepatic disorder.
  • eGFR \<25 ml/ min/ 1.73 m2 or as per clinical judgment.
  • Plasma and/or serum glucose \>300 or as per clinical judgment. Clinical History Exclusion Criteria
  • Human immunodeficiency virus infection.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Mayo Clinic in Rochester — Rochester, Minnesota

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗